LTBK-04. PHASE 1 TRIAL OF WEE1 KINASE INHIBITOR ADAVOSERTIB (AZD1775) COMBINED WITH RADIATION THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP PHASE 1 PILOT CONSORTIUM (ADVL1217)

摘要

OBJECTIVESChildren with diffuse intrinsic pontine glioma (DIPG) continue to have dismal outcomes. AZD1775 is an orally available inhibitor of Wee1 kinase, a key G2-M checkpoint regulator that has been shown to cross the blood brain barrier and has demonstrated efficacy in preclinical studies of DIPG.